Full-Time
Updated on 9/3/2026
Global CRO delivering full-service clinical trials
No salary listed
Cincinnati, OH, USA
In Person
Office-based in Cincinnati, with occasional work from home potentially available after training for eligible positions.
PhD
See people who can refer or advise you
Medpace is a global Contract Research Organization that provides end-to-end clinical development services for pharmaceutical, biotechnology, and medical device leaders. It runs Phase I–IV trials from study design through regulatory submissions, monitoring, data management, statistics, medical writing, and final reporting. A unique feature is ownership of integrated laboratories—global central labs, a bioanalytical lab, and imaging/ECG core labs—that streamline workflows and ensure data consistency. Its goal is to help sponsors bring therapies to market efficiently by coordinating all trial activities under a physician-led, scientifically driven team.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Cincinnati, Ohio
Founded
1992
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Flexible Work Hours
Unlimited Paid Time Off
Competitive Compensation and Benefits Package
Employee Health and Wellness Initiatives
Hybrid Work Options
Structured Career Paths with Opportunities for Professional Growth
Hsbc Holdings PLC bought a new position in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 977 shares of the company’s stock, valued at approximately $518,000. Several other hedge funds and other institutional […]
Medpace reported revenues of $707.3 million in Q2, up 17.2% year on year, exceeding analyst expectations by 2.6%. The contract research organisation, which provides outsourced clinical trial management services to pharmaceutical and biotech companies, achieved the fastest revenue growth among eight drug development inputs and services stocks tracked. The company's full-year revenue guidance surpassed analyst expectations. The sector overall performed strongly, with revenues beating consensus estimates by 4.1% and share prices rising 10.5% on average since earnings. Medpace's stock rose 10.2% following the results and currently trades at $582.23. The drug development inputs and services industry benefits from stable demand as pharmaceutical companies outsource non-core functions through medium to long-term contracts.
Medpace reported second-quarter revenue of $707.3 million, exceeding analyst estimates of $689.7 million and marking 17.2% year-on-year growth. The clinical research company's GAAP profit of $4.25 per share beat consensus estimates by 6.6%. The company raised its full-year revenue guidance to $2.85 billion at the midpoint, up from $2.81 billion previously. Full-year EPS guidance of $17.60 at the midpoint came in 3.9% above analyst expectations. Medpace's stock jumped 18.6% following the results. The company's adjusted EBITDA of $153.4 million also exceeded estimates, delivering a 21.7% margin. Despite the strong performance, analysts expect revenue to remain flat over the next 12 months, suggesting potential demand challenges ahead.
Clinical research company Medpace Holdings will report its second-quarter earnings on Wednesday after market hours. The market expects Medpace's revenue to grow 14.3% year on year this quarter, in line with the 14.2% increase it recorded in the same quarter last year. In the previous quarter, Medpace reported revenues of $706.6 million, up 26.5% year on year, beating analysts' expectations. The company also exceeded EPS estimates, though its full-year EPS guidance aligned with analysts' forecasts. Analysts covering the company have generally reconfirmed their estimates over the last 30 days. Medpace shares have risen 15.8% over the past month, outperforming the life sciences tools and services segment average of 9.9%.
Turtle Creek Asset Management added Medpace Holdings, Inc. (NASDAQ:MEDP) to its portfolio in Q1 2026, citing the clinical research organisation's differentiated strategy. The company focuses on small and mid-sized biopharma companies with full-service offerings, whilst competitors mainly serve Big Pharma with lower-margin work. Medpace's clinician-led model employs full-time MDs and PhDs to develop expertise in complex therapeutic areas. The founder-run company has demonstrated strong growth and cash flow generation. Its capital allocation approach is notably opportunistic, accumulating cash when shares are expensive and repurchasing aggressively when undervalued—buying back nearly 10% of outstanding shares last year. In Q1 2026, Medpace reported revenue of $706.6 million, up 26.5% year-over-year. Shares closed at $475.07, with a market capitalisation of $13.05 billion.